AI-Driven Discovery of Brain-Penetrant Galectin-3 Inhibitors for Alzheimer’s Disease Therapy.
AI identifies FJMU1887, a Gal-3 inhibitor, enhancing cognition and reducing neuroinflammation in Alzheimer’s models. 🧠💊
June 23, 2025
Follow us
latest articles
Discover the newest research about AI innovations in 🧪 Drug Discovery.
AI Identifies Non-Cancer Drugs That May Effectively Target Cancer Cells
AI identifies non-cancer drugs that may effectively target cancer cells. Promising combinations show potential for future research. 🧬💊
June 23, 2025
Applications of artificial intelligence in drug discovery for neurological diseases.
AI revolutionizes drug discovery for neurological diseases, enhancing molecule identification and treatment potential. 🤖💊
June 19, 2025
Artificial intelligence applications in rare and intractable diseases: Advances, challenges, and future directions.
AI transforms rare disease diagnosis and treatment, addressing 3.5%-5.9% of global cases. Key advancements and challenges discussed. 🤖💊
June 10, 2025
Newcastle Hospitals Develops Data Platform for Enhanced Medical Research
Newcastle Hospitals is enhancing medical research with a new data platform. This aims to improve patient outcomes and support innovation. 📊🏥
June 6, 2025
Invitation for Submissions: AI in Biomedical Engineering
AI in Biomedical Engineering: Call for Papers 📝🤖
Submissions welcome for research on AI’s role in medical advancements. Explore innovative applications and insights.
June 4, 2025
Enhancing search strategies for systematic reviews on drug Harms: An evaluation of the utility of ChatGPT in error detection and keyword generation.
ChatGPT enhances drug harm reviews: 49% keyword recreation, 0.17 Jaccard similarity. Effective error detection tool! 📊💊
May 30, 2025
National Taiwan University Hospital Launches AI for Pancreatic Cancer Imaging
National Taiwan University Hospital introduces AI for pancreatic cancer imaging, enhancing early detection and diagnostic accuracy. 🏥💻
May 28, 2025
Generative AI’s Role in Advancing Drug Development
Generative AI is enhancing drug development efficiency. The DiffSMol model shows a 61.4% success rate in creating promising drug candidates. 💊✨
May 27, 2025
Persist AI Raises $12 Million in Series A Funding and Launches Cloud Lab
Persist AI secures $12 million in funding and launches Cloud Lab, enhancing drug formulation efficiency with AI and robotics. 🤖💊
May 22, 2025